Plasma IL-8 As A Risk Stratification Tool For Adults With Septic Shock

Author(s):  
Carolyn S. Calfee ◽  
B. T. Thompson ◽  
Polly E. Parsons ◽  
Lorraine B. Ware ◽  
Michael A. Matthay ◽  
...  
2021 ◽  
Author(s):  
Peter Erdelyi ◽  
Laszlo Papp ◽  
Imre Foldesi ◽  
Katalin Farkas ◽  
Zsolt Molnar ◽  
...  

Abstract Background Sepsis is one of the most significant healthcare concerns of the 21st century. In the United States sepsis affect 1.7 million adults, with 270,000 fatal cases, according to the estimation of Centers for Disease Control and Prevention. The management of sepsis relies on early recognition, therefore the emergency departments have distinctive role in sepsis care, hence the need for early reliable risk stratification tools.Methods A retrospective, quantitative study was performed in Department of Emergency, University of Szeged. Hungary. Patients with suspected infection were enrolled to four subgroups based on the results of patient examination and laboratory results. In all cases (N=276), cell population data markers were analyzed along with ordinary infection biomarkers, such as CRP, PCT and WBC. Performance of cell population data parameters were investigated with ROC (Receiver Operating Curve) analysis.Results Almost all cell population biomarkers showed significant differences in the subgroup analysis. Remarkable performance was found in three markers (NE-SFL/M, MO-X/M and NE-WY/M) in patients having septic shock. Combining quick SOFA with these biomarkers (qS-Ne2Mo score) resulted in excellent diagnostic ability for septic shock (AUC 0.914, p<0.001), with good sensitivity (73.9%) and excellent specificity (89 %).Conclusions Since determination of cell population data requires complete blood count analysis, turn-around time of this novel indicator is significantly lower than other methods. qS-Ne2Mo score might be used as an initial screening tool to select only those patients that need more extensive laboratory investigations for their proper treatment and spare inadequate, time and money consuming laboratory requests.Trial Registration: University of Szeged, Ethical Committee ref. nr. 25/2016-SZTE


2010 ◽  
Vol 38 (6) ◽  
pp. 1436-1441 ◽  
Author(s):  
Carolyn S. Calfee ◽  
B. Taylor Thompson ◽  
Polly E. Parsons ◽  
Lorraine B. Ware ◽  
Michael A. Matthay ◽  
...  

Author(s):  
Massimo Imazio ◽  
Alessandro Andreis ◽  
Marta Lubian ◽  
George Lazaros ◽  
Emilia Lazarou ◽  
...  

2011 ◽  
Vol 55 (10) ◽  
pp. 4581-4588 ◽  
Author(s):  
Carol L. Moore ◽  
Mei Lu ◽  
Faiqa Cheema ◽  
Paola Osaki-Kiyan ◽  
Mary Beth Perri ◽  
...  

ABSTRACTMethicillin-resistantStaphylococcus aureus(MRSA) is a common cause of bloodstream infection (BSI) and is often associated with invasive infections and high rates of mortality. Vancomycin has remained the mainstay of therapy for serious Gram-positive infections, particularly MRSA BSI; however, therapeutic failures with vancomycin have been increasingly reported. We conducted a comprehensive evaluation of the factors (patient, strain, infection, and treatment) involved in the etiology and management of MRSA BSI to create a risk stratification tool for clinicians. This study included consecutive patients with MRSA BSI treated with vancomycin over 2 years in an inner-city hospital in Detroit, MI. Classification and regression tree analysis (CART) was used to develop a risk prediction model that characterized vancomycin-treated patients at high risk of clinical failure. Of all factors, the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, with a cutoff point of 14, was found to be the strongest predictor of failure and was used to split the population into two groups. Forty-seven percent of the population had an APACHE-II score < 14, a value that was associated with low rates of clinical failure (11%) and mortality (4%). Fifty-four percent of the population had an APACHE-II score ≥ 14, which was associated with high rates of clinical failure (35%) and mortality (23%). The risk stratification model identified the interplay of three other predictors of failure, including the vancomycin MIC as determined by Vitek 2 analysis, the risk level of the source of BSI, and the USA300 strain type. This model can be a useful tool for clinicians to predict the likelihood of success or failure in vancomycin-treated patients with MRSA bloodstream infection.


HPB ◽  
2020 ◽  
Vol 22 ◽  
pp. S353-S354
Author(s):  
G. Morris-Stiff ◽  
S Shashank Sarvepalli ◽  
N. Gupta ◽  
P. Lal ◽  
M. Matta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document